Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Other Hematologic Malignant Neoplasms
Conditions
Brief summary
To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic malignancy where HSCT is indicated.
Detailed description
Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other hematologic malignancy where HSCT is indicated with the use of a regulatory T cell based protocol. Hyper-fractionated Total Body Irradiation or Total Marrow and Lymphoid Irradiation based conditioning will be followed by the infusion of T regulatory and T conventional cell adoptive immunotherapy and a purified CD34+ hematopoietic stem cell graft. Incidence of Non Relapse Mortality, Relapse, acute Graft versus Host Disease, chronic Graft versus Host Disease, as well as probability of cGvHD/disease free survival will be assessed in patient subpopulations separated according to HLA-matching with the donor (HLA-matched HSCT and HLA-haploidentical HSCT) and type of disease (acute myeloid leukemia, acute lymphoid leukemia, lymphoma, multiple myeloma, myeloproliferative disease, and other).
Interventions
BIOLOGICALHigh dose irradiation conditioning + Treg/Tcon
High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
Sponsors
University Of Perugia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 75 Years
Healthy volunteers
No
Inclusion criteria
* AML and ALL in complete remission and with high-risk of relapse * AML and ALL primarily chemoresistant or relapsed; * Chronic Myeloid Leukemia in accelerated or blastic phase; * Patients affected by * Multiple myeloma, * Non Hodgkin lymphoma, * Hodgkin lymphoma, * Chronic myeloproliferative syndrome, * Chronic Lymphoid Leukemia, * Other Hematological malignancy at high-risk of relapse or detectable disease and where a HSCT is indicated. * Age \<75 years * ECOG ≤ 2 * Acceptable lung, liver, kidney, and heart function and absence of relevant psichiatric diseases * Signature of the informed consent
Exclusion criteria
* Age \>75 years * ECOG \> 2 * Not acceptable lung, liver, kidney, and heart function and presence of relevant psichiatric diseases * Pregnancy * No signature of the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| chronic GvHD/relapse-free survival | 2 years | To evaluate if irradiation based myeloablative conditioning followed by Treg/Tcon adoptive immunotherapy improve chronic GvHD/relapse-free survival (GRFS) after allogeneic HSCT in patients affected by acute leukemias or other hematologic malignancies where HSCT is indicated. GRFS will be assessed in subgroups of patients separated according to HLA-matching with the donor and type of disease (acute myeloid lekemia, acute lymphoid leukemia, other) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| full donor-type engraftment | 30 days | neutrophil and platelet engraftment measured by neutrophil counts \>500/mmc for 3 consecutive days and platelets count \>20000/mmc with 7 consecutive without platelet transfusion |
Other
| Measure | Time frame | Description |
|---|---|---|
| cumulative incidence of grades ≥ 2 acute GvHD | 6 months | cumulative incidence of grades ≥ 2 acute GvHD according to NIH consesus criteria |
| cumulative incidence of extensive chronic GvHD | 2 years | cumulative incidence of extensive chronic GvHD according to revised NIH consesus criteria (Jagasia et al. BBMT 2015) |
| cumulative incidence of non-relapse mortality | 2 years | cumulative incidence of non-relapse mortality, defined as death by any cause in the absence of relapse, as competitive risk versus relapse |
| cumulative incidence of relapse | 2 years | cumulative incidence of relapse, defined as disease recurrence according to marrow morphology, flow cytometry, cytogenetics, fluorescence in situ hybridization and/or polymerase chain reaction, as competitive risk versus non-relapse mortality |
Countries
Italy
Contacts
Primary ContactAntonio Pierini, MD, PhD
Backup ContactMara Merluzzi, MBioTech
Outcome results
None listed